Phase II Trial of Individualized Immunotherapy in Early-Stage Unfavorable Classical Hodgkin Lymphoma
NCT04837859
·
clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
120
Enrollment
OTHER
Sponsor class
Conditions
Classical Hodgkin Lymphoma
Interventions
DRUG:
Tislelizumab
Sponsor
University of Cologne